High prevalence of raised lipoprotein(a) in patients with refractory angina
- PMID: 26779510
- PMCID: PMC4614330
- DOI: 10.5339/gcsp.2015.28
High prevalence of raised lipoprotein(a) in patients with refractory angina
Abstract
Background: Angina that is refractory to conventional medical therapy and revascularisation, remains challenging to manage and poses significant burden to patients. Elevated lipoprotein(a) [Lp(a)] has emerged as an important independent cardiovascular risk factor and predictor of adverse outcomes in atherosclerotic disease. The prevalence of raised Lp(a) amongst patients with refractory angina has not yet been defined.
Objective: To establish the prevalence of raised [Lp(a)] >500 mg/L in patients with refractory angina.
Methods: We conducted an epidemiological screening pilot study in 75 patients with refractory angina from a UK tertiary cardiac centre. We determined the proportion of the cohort with raised Lp(a) >500 mg/L using an isoform-insensitive method. In addition, a full fasting lipid profile (including: LDL cholesterol, HDL cholesterol, total cholesterol to HDL ratio and triglycerides) was obtained. Patients were also asked about the presence of conventional cardiovascular risk factors.
Results: Our study demonstrated that 60% of the 75 patients with refractory angina had raised Lp(a) levels of >500 mg/L. The median and inter-quartile range of Lp(a) values were 771 mg/L (162 mg/L,1260 mg/L) respectively.
Conclusions: This high prevalence of raised Lp(a) detected in our cohort with refractory angina may suggest a causal role. Further research is necessary to confirm this association and prospective studies are needed to explore the potential therapeutic benefit of Lp(a) reduction in patients with refractory angina.
Keywords: Coronary artery disease; Lipoprotein (a); Refractory angina; Risk factors.
Figures
Similar articles
-
The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial.Atheroscler Suppl. 2015 May;18:103-8. doi: 10.1016/j.atherosclerosissup.2015.02.019. Atheroscler Suppl. 2015. PMID: 25936312 Clinical Trial.
-
The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina.Glob Cardiol Sci Pract. 2014 Jan 29;2014(1):3-12. doi: 10.5339/gcsp.2014.3. eCollection 2014. Glob Cardiol Sci Pract. 2014. PMID: 25054114 Free PMC article. Review.
-
Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a).Antioxidants (Basel). 2021 Jan 18;10(1):132. doi: 10.3390/antiox10010132. Antioxidants (Basel). 2021. PMID: 33477712 Free PMC article.
-
Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study.Atherosclerosis. 2002 Aug;163(2):377-84. doi: 10.1016/s0021-9150(02)00026-6. Atherosclerosis. 2002. PMID: 12052486
-
Lipoprotein(a), cardiovascular disease, and contemporary management.Mayo Clin Proc. 2013 Nov;88(11):1294-311. doi: 10.1016/j.mayocp.2013.09.003. Mayo Clin Proc. 2013. PMID: 24182706 Review.
Cited by
-
Lipoprotein(a): the underutilized risk factor for cardiovascular disease.Glob Cardiol Sci Pract. 2019 Sep 20;2019(2):e201911. doi: 10.21542/gcsp.2019.11. Glob Cardiol Sci Pract. 2019. PMID: 31799286 Free PMC article.
-
Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial.Eur Heart J. 2017 May 21;38(20):1561-1569. doi: 10.1093/eurheartj/ehx178. Eur Heart J. 2017. PMID: 28453721 Free PMC article. Clinical Trial.
References
-
- Kim MC, Kini A, Sharma SK. Refractory angina pectoris. Mechanism and therapeutic options. J Am Coll Cardiol. 2002;39(6):923–934. - PubMed
-
- Mannheimer C, Camici P, Chester MR, Collins A, DeJongste M, Eliasson T, Follath F, Hellemans I, Herlitz J, Lüscher T, Pasic M, Thelle D. The problem of chronic refractory angina; report from the ESC joint study group on the treatment of refractory angina. Eur Heart J. 2002;23(5):355–370. - PubMed
-
- Soran O. Treatment options for refractory angina pectoris: Enhanced external counterpulsation therapy. Curr Treat Options Cardiovasc Med. 2009;11:54–60. - PubMed
-
- Manchanda A, Aggarwal A, Aggarwal N, Soran O. Management of refractory angina pectoris. Cardiology Journal. 2011;18(4):343–351. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous